Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Vaccination as a therapy: Experimental vaccine against cervical cancer successfully tested in mice

No. 03 | 16/01/2019 | by Eck

Scientists from the German Cancer Research Center (DKFZ) have developed an experimental vaccine to fight cervical cancer caused by human papillomaviruses (HPV). This has already been accomplished successfully in mice. Tumors regressed in half of the vaccinated animals. The scientists' goal is to develop a therapeutic vaccine for people who are already suffering from cancer or cancer precursors and, thus, no longer benefit from preventive vaccination.

Computer-generated simulation of a HPV

Cervical cancer is the third most frequent cancer in women worldwide. It is caused by human papillomaviruses (HPV) that infect cells of the cervical mucosa and cause them to grow out of control. Infection with HPV can also cause anal cancer and cancers of the oral cavity. Preventive vaccines are available for preventing infection with the cancer-causing viruses. However, this HPV vaccination is ineffective in people who have already been exposed to the virus. In addition, vaccination rates are low. Despite existing vaccination recommendations – by now also for boys – by the Standing Committee on Vaccination (STIKO), only half of the girls aged 17 in Germany have been vaccinated.

"Our goal is to develop a therapeutic vaccine for treating individuals that have already contracted HPV infection and may already have developed HPV-induced cancer or precancerous lesions," said Angelika Riemer from the German Cancer Research Center (DKFZ). "A therapeutic vaccine stimulates the immune system and causes it to attack and kill infected or transformed cells."

One of the major differences between preventive and therapeutic vaccines is the time of vaccination: A preventive vaccine is only effective if it is administered before an infection has taken place. By contrast, a therapeutic vaccine is used to treat already existing infections and their consequences.

Another difference between preventive and therapeutic vaccinations is apparent in the immune system's response. Following a preventive vaccination, the body develops antibodies that protect it from future infection with the pathogen. A therapeutic vaccination, however, activates cytotoxic T cells. These immune cells are capable of recognizing minute molecular structures of the papillomaviruses, called epitopes, which are displayed on the surface of infected cells or cancer cells, thus identifying them as suspicious, and eliminating these cells.

Riemer and her colleagues have already been able to show in mice that their experimental vaccine is effective against HPV-associated cancers. "The tumors regressed completely in half of the vaccinated animals," reported the DKFZ researcher.

The key component of the vaccine are the epitopes which HPV-associated tumors also exhibit on their surface. Following vaccination, these protein structures are carried into the lymph nodes. "This is particularly efficient in order to trigger an immune response because this is where all immune cells responsible for an immune response are present," said Riemer.

In this case, the cytotoxic T cells are crucial. When they come into contact with the epitopes from the vaccine, this is a signal for them to start searching the rest of the body for cells which also display these recognition molecules. If the cytotoxic T cells encounter cancer cells carrying these HPV epitopes on their surface, they destroy them.

The therapeutic vaccine against cervical cancer and other HPV-associated cancer types is currently still in the preclinical development stage. A couple of hurdles must be overcome before it will be possible to use it in humans. "The effectiveness of the vaccination must be increased," said Riemer.

Experience from the development of therapeutic vaccines against other cancers has shown that a vaccine is in some cases more effective if it contains more than one recognition molecule. "However, in our first experiment in mice it was the opposite," Riemer reports. "Maybe for HPV tumors it is better to use only one recognition molecule which is a really good one. But we need further investigations to verify this."

Sebastian Kruse, Marleen Büchler, Philipp Uhl, Max Sauter, Philipp Scherer, Tammy C.T. Lan, Samantha Zottnick, Alexandra Klevenz, Ruwen Yang, Frank Rösl, Walter Mier & Angelika B. Riemer: Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model
OncoImmunology 8:1, e1524694, DOI:10.1080/2162402X.2018.1524694

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS